Pfizer stock: outlook cut and patent cliff drive 3.37% daily loss

Traders Union
All News
Financial News
Pfizer slides 3.37% today on outlook

Highlights

Pfizer revised its 2025 revenue guidance to $62 billion, the lower end of its prior range, citing reduced COVID-19 vaccine and treatment revenues.
Projected 2026 earnings per share of $2.80 to $3.00 fall below Wall Street expectations due to patent expirations and pricing pressure from U.S. government agreements.
Pfizer declared a $0.43 dividend for Q1 2026 and will emphasize dividend payouts over buybacks, while continuing investments in partnerships and R&D.

Lower guidance and dividend focus as covid revenue fades

Pfizer has updated its outlook, warning of challenging years ahead as revenues from its COVID-19 vaccine and treatment decline, coupled with upcoming patent expirations and pricing pressure from U.S. government agreements. The company revised its 2025 revenue guidance to $62 billion, at the lower end of its previous range, and set 2026 earnings per share at $2.80 to $3.00, below Wall Street expectations. Despite these headwinds, Pfizer reaffirmed its commitment to shareholder returns by declaring a $0.43 dividend for the first quarter of 2026 and focusing capital allocation on dividends over buybacks, while also noting ongoing investment in partnerships and R&D.

Mixed momentum with weak trend and conflicting oscillator signals

Momentum signals on the daily chart are mixed: the MACD suggests a mild bullish bias while the ADX indicates a weak and indecisive trend. Oscillators send conflicting signals, with RSI neutral to slightly positive, Stoch RSI in oversold territory, and CCI neutral. A strong overbought reading from Bull/Bear Power points to buyer dominance though some exhaustion, while the Awesome Oscillator remains neutral, not confirming the move. The Kijun at $25.28 is the closest dynamic support, and MA-50 near $25.11 provides additional downside protection if the price drops further.

Sideways trade expected as volatility and drivers stay balanced

For the upcoming week, PFE is likely to fluctuate within a typical volatility band between $24.70 and $25.95. The technical outlook is balanced, with around a 50% chance of either a move higher or lower as momentum indicators and moving averages remain split. The base scenario points to sideways trading within this range. If bullish pressure prevails and the price surpasses $26.00, further upside may follow, while a break below $24.70 could result in additional selling pressure toward longer-term support levels.

Anton Kharitonov, Traders Union analyst, notes that Pfizer’s technicals suggest indecision and limited momentum while fundamentals are pressured by fading COVID-19 revenues, patent risks, and below-consensus guidance. He sees no clear near-term catalyst, as oscillators and moving averages offer little conviction on direction. The analyst remains critical and defensive in his tactical view, emphasizing potential for sideways movement within the $24.70–$25.95 range. "Base case is to avoid taking new positions until sustained momentum or decisive break from this range emerges."

Previously it was reported that Pfizer Inc. maintains a bullish technical bias, trading above its key short-, medium-, and long-term moving averages, with mild positive momentum signals as reflected by a MACD buy and neutral ADX, though most oscillators now indicate overbought conditions. Dynamic support appears near $25.28, while price action faces resistance at the $26 round number, suggesting the stock may consolidate within a narrowing volatility band unless a breakout or breakdown occurs.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.